<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>åˆ¶è¯æ—¥æŠ¥ - 2026-01-23</title>
    <style>
        :root, [data-theme="minimal"] {
            --bg-primary: #ffffff;
            --bg-secondary: #f5f5f7;
            --text-primary: #1d1d1f;
            --text-secondary: #86868b;
            --accent: #0071e3;
            --accent-hover: #0077ed;
            --border: #d2d2d7;
            --card-shadow: 0 4px 6px -1px rgba(0, 0, 0, 0.05);
            --header-bg: transparent;
            --header-text: var(--text-primary);
        }

        [data-theme="pharma-blue"] {
            --bg-primary: #f0f4f8;
            --bg-secondary: #ffffff;
            --text-primary: #2d3748;
            --text-secondary: #718096;
            --accent: #2b6cb0;
            --accent-hover: #2c5282;
            --border: #e2e8f0;
            --card-shadow: 0 4px 6px -1px rgba(0, 0, 0, 0.1), 0 2px 4px -1px rgba(0, 0, 0, 0.06);
            --header-bg: linear-gradient(135deg, #1a365d 0%, #2b6cb0 100%);
            --header-text: #ffffff;
        }

        [data-theme="warm"] {
            --bg-primary: #faf8f5;
            --bg-secondary: #ffffff;
            --text-primary: #451a03;
            --text-secondary: #78716c;
            --accent: #d97706;
            --accent-hover: #b45309;
            --border: #e7e5e4;
            --card-shadow: 0 1px 3px 0 rgba(0, 0, 0, 0.1);
            --header-bg: transparent;
            --header-text: var(--text-primary);
        }

        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "SF Pro Display", "SF Pro Text", "Helvetica Neue", "PingFang SC", "Microsoft YaHei", sans-serif;
            background: var(--bg-primary);
            color: var(--text-primary);
            line-height: 1.5;
            -webkit-font-smoothing: antialiased;
        }

        .container {
            max-width: 980px;
            margin: 0 auto;
            padding: 0 22px;
        }

        /* Header */
        header {
            padding: 80px 0 60px;
            text-align: center;
        }

        .logo {
            font-size: 48px;
            margin-bottom: 16px;
        }

        h1 {
            font-size: 48px;
            font-weight: 600;
            letter-spacing: -0.02em;
            margin-bottom: 8px;
        }

        .subtitle {
            font-size: 21px;
            color: var(--text-secondary);
            font-weight: 400;
        }

        /* Stats */
        .stats-bar {
            display: flex;
            justify-content: center;
            gap: 48px;
            padding: 32px 0;
            margin: 40px 0;
            border-top: 1px solid var(--border);
            border-bottom: 1px solid var(--border);
        }

        .stat {
            text-align: center;
        }

        .stat-value {
            font-size: 32px;
            font-weight: 600;
            color: var(--text-primary);
        }

        .stat-label {
            font-size: 14px;
            color: var(--text-secondary);
            margin-top: 4px;
        }

        /* Analysis Section */
        .analysis {
            background: var(--bg-secondary);
            border-radius: 18px;
            padding: 32px;
            margin-bottom: 48px;
        }

        .analysis h2 {
            font-size: 24px;
            margin-bottom: 16px;
        }

        .analysis-content {
            font-size: 17px;
            line-height: 1.7;
            color: var(--text-secondary);
        }

        /* Category Section */
        .category {
            margin-bottom: 56px;
        }

        .category-header {
            display: flex;
            align-items: baseline;
            gap: 12px;
            margin-bottom: 24px;
            padding-bottom: 12px;
            border-bottom: 1px solid var(--border);
        }

        .category-title {
            font-size: 28px;
            font-weight: 600;
        }

        .category-title-en {
            font-size: 17px;
            color: var(--text-secondary);
            font-weight: 400;
        }

        .category-count {
            background: var(--bg-secondary);
            color: var(--text-secondary);
            padding: 4px 12px;
            border-radius: 20px;
            font-size: 14px;
            margin-left: auto;
        }

        /* News Card */
        .news-card {
            background: var(--bg-primary);
            border: 1px solid var(--border);
            border-radius: 18px;
            padding: 28px;
            margin-bottom: 16px;
            transition: all 0.3s ease;
        }

        .news-card:hover {
            box-shadow: var(--card-shadow);
            transform: translateY(-2px);
        }

        .news-card h3 {
            font-size: 21px;
            font-weight: 600;
            margin-bottom: 12px;
            line-height: 1.4;
        }

        .news-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 16px;
            margin-bottom: 16px;
            font-size: 14px;
            color: var(--text-secondary);
        }

        .news-source {
            color: var(--accent);
            font-weight: 500;
        }

        .news-importance {
            letter-spacing: 2px;
        }

        .news-summary {
            font-size: 17px;
            color: var(--text-secondary);
            line-height: 1.6;
            margin-bottom: 16px;
        }

        .news-link {
            display: inline-flex;
            align-items: center;
            gap: 6px;
            color: var(--accent);
            text-decoration: none;
            font-size: 17px;
            font-weight: 500;
            transition: color 0.2s;
        }

        .news-link:hover {
            color: var(--accent-hover);
        }

        .news-link::after {
            content: "â†’";
            transition: transform 0.2s;
        }

        .news-link:hover::after {
            transform: translateX(4px);
        }

        /* Footer */
        footer {
            text-align: center;
            padding: 48px 0;
            color: var(--text-secondary);
            font-size: 14px;
            border-top: 1px solid var(--border);
            margin-top: 48px;
        }

        footer p {
            margin-bottom: 8px;
        }

        /* Language Flag */
        .lang-flag {
            font-size: 16px;
            margin-right: 8px;
        }

        /* Date Filter */
        .date-filter {
            display: flex;
            justify-content: center;
            gap: 8px;
            flex-wrap: wrap;
            margin-bottom: 32px;
        }

        .date-btn {
            padding: 8px 16px;
            border: 1px solid var(--border);
            border-radius: 20px;
            background: var(--bg-primary);
            color: var(--text-secondary);
            font-size: 14px;
            cursor: pointer;
            transition: all 0.2s ease;
            display: flex;
            flex-direction: column;
            align-items: center;
            min-width: 70px;
        }

        .date-btn:hover {
            border-color: var(--accent);
            color: var(--accent);
        }

        .date-btn.active {
            background: var(--accent);
            border-color: var(--accent);
            color: white;
        }

        .date-btn.weekend {
            background: var(--bg-secondary);
        }

        .date-btn.weekend.active {
            background: var(--accent);
        }

        .date-btn .weekday {
            font-size: 12px;
            opacity: 0.8;
        }

        .date-btn .date-display {
            font-weight: 500;
        }

        .filter-count {
            text-align: center;
            color: var(--text-secondary);
            font-size: 14px;
            margin-bottom: 24px;
        }

        .news-card.hidden {
            display: none;
        }

        /* Theme Switcher */
        .theme-switcher {
            position: fixed;
            top: 20px;
            right: 20px;
            display: flex;
            gap: 8px;
            background: var(--bg-secondary);
            padding: 8px;
            border-radius: 12px;
            box-shadow: 0 2px 10px rgba(0, 0, 0, 0.1);
            z-index: 1000;
        }

        .theme-btn {
            width: 32px;
            height: 32px;
            border: 2px solid transparent;
            border-radius: 8px;
            cursor: pointer;
            transition: all 0.2s ease;
            position: relative;
        }

        .theme-btn:hover {
            transform: scale(1.1);
        }

        .theme-btn.active {
            border-color: var(--accent);
        }

        .theme-btn[data-theme="minimal"] {
            background: linear-gradient(135deg, #ffffff 50%, #0071e3 50%);
        }

        .theme-btn[data-theme="pharma-blue"] {
            background: linear-gradient(135deg, #1a365d 50%, #2b6cb0 50%);
        }

        .theme-btn[data-theme="warm"] {
            background: linear-gradient(135deg, #faf8f5 50%, #d97706 50%);
        }

        /* Responsive */
        @media (max-width: 734px) {
            header {
                padding: 48px 0 40px;
            }

            h1 {
                font-size: 32px;
            }

            .subtitle {
                font-size: 17px;
            }

            .stats-bar {
                gap: 24px;
            }

            .stat-value {
                font-size: 24px;
            }

            .category-title {
                font-size: 24px;
            }

            .news-card {
                padding: 20px;
            }

            .news-card h3 {
                font-size: 19px;
            }
        }
    </style>
</head>
<body>
    <!-- Theme Switcher -->
    <div class="theme-switcher">
        <button class="theme-btn active" data-theme="minimal" title="ç®€çº¦ç™½"></button>
        <button class="theme-btn" data-theme="pharma-blue" title="åŒ»è¯è“"></button>
        <button class="theme-btn" data-theme="warm" title="æš–è‰²è°ƒ"></button>
    </div>

    <div class="container">
        <header>
            <div class="logo">ğŸ’Š</div>
            <h1>åˆ¶è¯æ—¥æŠ¥</h1>
            <p class="subtitle">Pharma Daily Â· 2026-01-23 <span style="font-size: 14px; opacity: 0.7;">(US Eastern / EST)</span></p>
        </header>

        <div class="stats-bar">
            <div class="stat">
                <div class="stat-value">102</div>
                <div class="stat-label">æ–°é—»æ€»æ•°</div>
            </div>
            <div class="stat">
                <div class="stat-value">4</div>
                <div class="stat-label">ç±»åˆ«æ•°</div>
            </div>
            <div class="stat">
                <div class="stat-value">2026-01-24 03:25</div>
                <div class="stat-label">æ›´æ–°æ—¶é—´</div>
            </div>
        </div>

        <!-- Date Filter -->
        <div class="date-filter">
            <button class="date-btn active" data-filter="all">
                <span class="weekday">å…¨éƒ¨</span>
                <span class="date-display">All</span>
            </button>
            
            <button class="date-btn weekend" data-filter="2026-01-17">
                <span class="weekday">å‘¨å…­</span>
                <span class="date-display">01/17</span>
            </button>
            
            <button class="date-btn weekend" data-filter="2026-01-18">
                <span class="weekday">å‘¨æ—¥</span>
                <span class="date-display">01/18</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-19">
                <span class="weekday">å‘¨ä¸€</span>
                <span class="date-display">01/19</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-20">
                <span class="weekday">å‘¨äºŒ</span>
                <span class="date-display">01/20</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-21">
                <span class="weekday">å‘¨ä¸‰</span>
                <span class="date-display">01/21</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-22">
                <span class="weekday">å‘¨å››</span>
                <span class="date-display">01/22</span>
            </button>
            
            <button class="date-btn " data-filter="2026-01-23">
                <span class="weekday">å‘¨äº”</span>
                <span class="date-display">01/23</span>
            </button>
            
        </div>
        <div class="filter-count" id="filterCount"></div>

        
        <section class="analysis">
            <h2>ğŸ“Š ä»Šæ—¥æ¦‚è§ˆ</h2>
            <div class="analysis-content">
                <h3>ğŸ“Š AI æ™ºèƒ½åˆ†æ</h3>
<h4>ä»Šæ—¥æ¦‚è§ˆ</h4>
<p>ä»Šæ—¥åˆ¶è¯è¡Œä¸šåŠ¨æ€èšç„¦äºé‡ç£…è¯ç‰©ä¸´åºŠè¿›å±•ä¸ç›‘ç®¡æ”¿ç­–å˜åŒ–ã€‚è¯ºå’Œè¯ºå¾·å£æœWegovyä¸Šå¸‚åˆæœŸè¡¨ç°å¼ºåŠ²ï¼Œå¼ºç”Ÿé¢„è®¡2026å¹´è¥æ”¶å°†çªç ´1000äº¿ç¾å…ƒï¼›FDAå‘å¸ƒå¤šå‘æ€§éª¨é«“ç˜¤è¯ç‰©å¼€å‘æ–°æŒ‡å—ï¼Œæœ‰æœ›åŠ é€Ÿç»†èƒç–—æ³•ç­‰åˆ›æ–°è¯å®¡æ‰¹ã€‚åŒæ—¶ï¼Œèµ›è¯ºè²æ¹¿ç–¹è¯ç‰©IIIæœŸæ•°æ®å–œå¿§å‚åŠï¼Œç”Ÿç‰©ç±»ä¼¼è¯é¢†åŸŸè¿æ¥ä¹è§‚å±•æœ›ã€‚</p>
<h4>ğŸ”¥ é‡ç‚¹æ–°é—»</h4>
<p><strong>10. Novo's Wegovy pill launch wows with strong early uptake: analysts</strong> â­â­â­â­â­<br>
   - ç±»åˆ«: å¸‚åœºåˆ†æ<br>
   - å£æœå‡è‚¥è¯Wegovyä¸Šå¸‚åˆæœŸå¤„æ–¹é‡è¡¨ç°å¼ºåŠ²ï¼Œé¢„ç¤ºå£æœGLP-1è¯ç‰©å¯èƒ½é‡å¡‘è‚¥èƒ–ç—‡æ²»ç–—å¸‚åœºæ ¼å±€ã€‚</p>
<p><strong>13. Led by Darzalex surge, J&J expects revenue to reach $100B in 2026</strong> â­â­â­â­â­<br>
   - ç±»åˆ«: å¸‚åœºåˆ†æ<br>
   - å¼ºç”Ÿé¦–æ¬¡é¢„æµ‹2026å¹´è¥æ”¶å°†çªç ´1000äº¿ç¾å…ƒï¼Œåæ˜ å…¶æ ¸å¿ƒäº§å“ï¼ˆå¦‚Darzalexï¼‰çš„å¼ºåŠ²å¢é•¿åŠ¿å¤´åŠè¡Œä¸šå·¨å¤´çš„å‘å±•ä¿¡å¿ƒã€‚</p>
<p><strong>16. FDA lays out new path to speed development of multiple myeloma drugs</strong> â­â­â­â­â­<br>
   - ç±»åˆ«: æ”¿ç­–æ³•è§„<br>
   - FDAå‘å¸ƒæ–°æŒ‡å—ï¼Œå…è®¸åŸºäºå¾®å°æ®‹ç•™ç—…ï¼ˆMRDï¼‰ä½œä¸ºä¸»è¦ç»ˆç‚¹åŠ é€Ÿå¤šå‘æ€§éª¨é«“ç˜¤è¯ç‰©å®¡æ‰¹ï¼Œå°†æ˜¾è‘—åŠ é€Ÿç»†èƒç–—æ³•ç­‰åˆ›æ–°è¯å¼€å‘è¿›ç¨‹ã€‚</p>
<p><strong>2. Sanofi's Phase 3 eczema data cloud hopes for potential immunology blockbuster</strong> â­â­â­â­<br>
   - ç±»åˆ«: ä¸´åºŠè¯•éªŒ<br>
   - èµ›è¯ºè²æ½œåœ¨é‡ç£…å…ç–«è¯ç‰©åœ¨æ¹¿ç–¹é€‚åº”ç—‡çš„IIIæœŸæ•°æ®å–œå¿§å‚åŠï¼Œå¯èƒ½å½±å“å…¶æˆä¸ºâ€œé‡ç£…ç‚¸å¼¹â€è¯ç‰©çš„å‰æ™¯åŠå¸‚åœºç«äº‰æ ¼å±€ã€‚</p>
<p><strong>12. Biosimilar execs optimistic about future for US biosims as Sandoz locks in on â€˜golden decadeâ€™ to come</strong> â­â­â­â­<br>
   - ç±»åˆ«: å¸‚åœºåˆ†æ<br>
   - è¡Œä¸šé«˜ç®¡å¯¹ç”Ÿç‰©ç±»ä¼¼è¯åœ¨ç¾å›½çš„æœªæ¥è¡¨ç¤ºä¹è§‚ï¼ŒFDAæ–°æŒ‡å—æœ‰æœ›ç®€åŒ–å¼€å‘æµç¨‹ï¼Œæ¨åŠ¨å¸‚åœºæ¸—é€è¿›å…¥â€œé»„é‡‘åå¹´â€ã€‚</p>
<h4>ğŸ“ åˆ†ç±»æ‘˜è¦</h4>
<p><strong>æ–°è¯ç ”å‘</strong> (Drug R&D): F2Gè®¡åˆ’é‡æ–°æäº¤æŠ—çœŸèŒè¯ï¼›IntraBioçš„ç½•è§ç—…è¯ç‰©åœ¨å¤šä¸ªé€‚åº”ç—‡å–å¾—ç§¯æè¿›å±•ï¼›Corvusæ¹¿ç–¹å£æœè¯æ—©æœŸæ•°æ®ç§¯æï¼›GSKä»¥22äº¿ç¾å…ƒæ”¶è´­RAPT Therapeuticsï¼Œè·å¾—é£Ÿç‰©è¿‡æ•åœ¨ç ”è¯ç‰©ã€‚<br>
<strong>ä¸´åºŠè¯•éªŒ</strong> (Clinical Trials): èµ›è¯ºè²æ¹¿ç–¹è¯ç‰©å…¬å¸ƒIIIæœŸæ•°æ®ï¼›Bausch Healthæ–°é…æ–¹IIIæœŸå¤±è´¥ï¼›IntraBioè¯ç‰©åœ¨å…±æµå¤±è°ƒ-æ¯›ç»†è¡€ç®¡æ‰©å¼ ç—‡IIIæœŸæˆåŠŸï¼›Corvusæ¹¿ç–¹å£æœè¯å…¬å¸ƒç§¯ææ—©æœŸæ•°æ®ã€‚</p>
<h4>ğŸ”® æ˜æ—¥å…³æ³¨</h4>
<p>å…³æ³¨FDAæ–°å¤šå‘æ€§éª¨é«“ç˜¤è¯ç‰©å¼€å‘æŒ‡å—çš„è¡Œä¸šå…·ä½“åé¦ˆåŠæ½œåœ¨å½±å“ï¼›è·Ÿè¸ªå£æœWegovyçš„åç»­å¸‚åœºå¤„æ–¹æ•°æ®åŠå¯¹è¯ºå’Œè¯ºå¾·è‚¡ä»·çš„å½±å“ï¼›ç•™æ„èµ›è¯ºè²æ˜¯å¦ä¼šåŸºäºæ··åˆæ•°æ®å¦‚æœŸæäº¤å…¶æ¹¿ç–¹è¯ç‰©çš„ä¸Šå¸‚ç”³è¯·ã€‚</p>
            </div>
        </section>
        

        <main>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">æ–°è¯ç ”å‘</h2>
                    <span class="category-title-en">Drug R&amp;D</span>
                    <span class="category-count">34 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        F2G CEO outlines biotech&#39;s FDA resubmission plans, funding and expansion
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-23 16:38</span>
                        
                        <span class="news-importance">â­â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">F2G plans to resubmit its antifungal to the FDA after collecting Phase 3 data this coming June, CEO Francesco Maria Lavino told Endpoints News. The biotech&#39;s oral candidate, called olorofim, was</p>
                    
                    <a href="https://endpoints.news/f2g-ceo-outlines-biotechs-fda-resubmission-plans-funding-and-expansion/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Sanofi&#39;s Phase 3 eczema data cloud hopes for potential immunology blockbuster
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-23 15:39</span>
                        
                        <span class="news-importance">â­â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The centerpiece of Sanofiâ€™s immunology efforts succeeded in two more Phase 3 eczema studies in the US, the company announced Friday, setting up a possible FDA submission before the end of ...</p>
                    
                    <a href="https://endpoints.news/sanofis-phase-3-eczema-data-cloud-hopes-for-potential-immunology-blockbuster/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Another biopharma tried buying Amicus before BioMarin&#39;s $4.8B deal
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-22 15:16</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The road to Amicus Therapeuticsâ€™ $4.8 billion exit to BioMarin last month included a previously undisclosed acquisition offer from another biopharma, quiet dinners between CEOs, and a months-long push to settle a ...</p>
                    
                    <a href="https://endpoints.news/another-biopharma-tried-buying-amicus-before-biomarins-4-8b-deal/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        J&amp;J praises new FDA guidance to speed development of multiple myeloma drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-21 18:35</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Johnson &amp;amp; Johnson, which has several drugs approved for multiple myeloma, praised the FDA&#39;s just-released draft guidance on how the agency will allow the use of minimal residual disease as a primary endpoint for accelerated ...</p>
                    
                    <a href="https://endpoints.news/jj-praises-new-fda-guidance-to-speed-development-of-multiple-myeloma-drugs/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        IntraBio says rare disease drug passes Phase 3, will seek FDA approval
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-21 16:05</span>
                        
                        <span class="news-importance">â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">IntraBio said Wednesday that its treatment improved motor function for a rare genetic disorder called ataxia-telangiectasia as part of a pivotal study. The Austin, TX-based biotech told Endpoints News it plans to submit an application ...</p>
                    
                    <a href="https://endpoints.news/intrabio-says-rare-disease-drug-passes-phase-3-will-seek-fda-approval/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Sanofi to seek approval of touted eczema drug despite mixed results
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-23 16:57</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Fresh data from multiple studies suggest the drug, which Sanofi has billed as a future blockbuster, could be cleared in the U.S. but has murky sales prospects.</p>
                    
                    <a href="https://www.biopharmadive.com/news/sanofi-amlitelimab-eczema-atopic-dermatitis-drug-results/810353/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Investors load Corxel with $287M for a â€˜differentiatedâ€™ obesity pill
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-22 19:00</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The funding will support a GLP-1 pill Corxel licensed from China-based Vincentage in 2024 and that the company believes to be as effective in spurring weight loss as injectable therapies.</p>
                    
                    <a href="https://www.biopharmadive.com/news/corxel-oral-glp1-vincentage-series-d-china-deal/810242/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        FDA lays out new path to speed development of multiple myeloma drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-22 16:36</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change that could accelerate cell therapies and other new medicines.&amp;nbsp;</p>
                    
                    <a href="https://www.biopharmadive.com/news/fda-multiple-myeloma-accelerated-approval-pathway/810219/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Corvus shares nearly triple on positive data for eczema pill
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-21 16:39</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">While early, the results indicate drugs known as ITK inhibitors have the potential to match or surpass the efficacy observed with the injectable biologic Dupixent.</p>
                    
                    <a href="https://www.biopharmadive.com/news/corvus-soquelitinib-phase-1-data-eczema-pill/810080/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        ACIP members depict diverging goals after schedule change
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-23 18:24</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Fresh off health officialsâ€™ sweeping remake of the US childhood vaccine schedule, two members of a key CDC panel are depicting different versions of the committeeâ€™s work moving forward. Comments made this week by Robert ...</p>
                    
                    <a href="https://endpoints.news/acip-members-depict-diverging-goals-after-schedule-change/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Former FDA deputies land at Lilly, AbbVie; Italy&#39;s Angelini has a new CEO
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-23 12:00</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">â†’ Eli Lilly is one of many large pharmas that have hired displaced or disgruntled FDA officials in the past year, and Karin Bok is its latest pickup. Bok resigned in November as deputy director ...</p>
                    
                    <a href="https://endpoints.news/former-fda-deputies-land-at-lilly-abbvie-italys-angelini-has-a-new-ceo/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Roche boosts NC factory investment to $2B; Rentschler CEO steps down
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-22 15:39</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Rocheâ€™s Genentech is topping up its investment into its Holly Springs, NC, factory to reach nearly $2 billion. The extra investment will also add an additional 100 jobs at the site ...</p>
                    
                    <a href="https://endpoints.news/roche-boosts-nc-factory-investment-to-2b-rentschler-ceo-steps-down/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novo climbs higher on â€˜strongâ€™ Wegovy pill launch; Terns tweaks leukemia drug deal
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-23 15:27</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Novo shares have surged more than 20% amid oral Wegovy&amp;rsquo;s fast start.&amp;nbsp;Elsewhere, Terns opened up room for a potential partnership and Corcept solidified its case for an ovarian cancer drug.</p>
                    
                    <a href="https://www.biopharmadive.com/news/wegovy-pill-prescriptions-terns-deal-corcept-data-biomerieux/810253/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Bristol Myers buys into Januxâ€™s â€˜maskedâ€™ T cell engagers
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-22 17:00</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Worth up to $850 million, the partnership provides &amp;ldquo;further validation&amp;rdquo; for Janux at a time of heightened investor scrutiny regarding the potential of its top drug, one analyst wrote.&amp;nbsp;</p>
                    
                    <a href="https://www.biopharmadive.com/news/janux-bristol-myers-partnership-t-cell-engagers-cancer/810227/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        EU kicks off one-year pilot to expedite multinational trials
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-23 19:24</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The European Union unveiled details of a pilot project that aims to accelerate the timeline for starting new multinational clinical trials. The voluntary pilot, called FASTâ€‘EU, will feature a maximum 10â€‘week (70â€‘day) timeline from drugmaker ...</p>
                    
                    <a href="https://endpoints.news/eu-kicks-off-one-year-pilot-to-expedite-multinational-trials/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Congress eyes tackling healthcare consolidation
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-23 14:42</span>
                        
                    </div>
                    
                    <p class="news-summary">&amp;ldquo;I think there&amp;rsquo;s common ground here,&amp;rdquo; one Republican congressman said Wednesday during a House Budget Committee hearing. Squaring up against healthcare monopolies would be a major pivot for the GOP.</p>
                    
                    <a href="https://www.biopharmadive.com/news/house-budget-committee-healthcare-affordability-consolidation/810333/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        BioMarin vets form Mendra to â€˜modernizeâ€™ rare disease drug development
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-22 16:02</span>
                        
                    </div>
                    
                    <p class="news-summary">Backed with $82 million and led by two of BioMarin&amp;rsquo;s former executives, Mendra&amp;nbsp;plans to acquire rare disease assets and use AI to help accelerate their development.</p>
                    
                    <a href="https://www.biopharmadive.com/news/mendra-rare-disease-biotech-startup-ai-biomarin-financing/810204/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        J&amp;J eyes $100B in sales amid gains for cancer, immune drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-21 16:04</span>
                        
                    </div>
                    
                    <p class="news-summary">Amid patent expirations, litigation and tariff costs, J&amp;amp;J says it expects more growth ahead, fueled in part by its blood cancer medicines and a closely watched psoriasis pill.</p>
                    
                    <a href="https://www.biopharmadive.com/news/johnson-johnson-2025-earnings-sales-cancer-immune-drugs/810097/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Moderna cancer vaccine holds up; IO Biotech considers a sale
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">BioPharma Dive</span>
                        <span class="news-date">2026-01-21 15:38</span>
                        
                    </div>
                    
                    <p class="news-summary">Long-term data suggest Moderna&amp;rsquo;s personalized melanoma shot provides &amp;ldquo;durable tumor control,&amp;rdquo; one analyst said. Elsewhere, Insilico Medicine partnered with a startup on a popular drug target.</p>
                    
                    <a href="https://www.biopharmadive.com/news/moderna-melanoma-io-biotech-nlrp3-think-pfizer-novavax/809958/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novo&#39;s Wegovy pill off to a solid start after just two weeks on market
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-23 20:23</span>
                        
                    </div>
                    
                    <p class="news-summary">Novo Nordiskâ€™s weight loss pill is off to an impressive start after less than three weeks on the market. Prescriptions are quickly ramping up, increasing by roughly 500% in the pillâ€™s second week, analysts said ...</p>
                    
                    <a href="https://endpoints.news/novos-wegovy-pill-off-to-a-solid-start-after-just-two-weeks-on-market/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Lilly was the only pharma bidder for Ventyx
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-23 12:20</span>
                        
                    </div>
                    
                    <p class="news-summary">Eli Lilly had very little competition in its eventual deal for Ventyx Biosciences, one of the leading drug developers in the hot NLRP3 arena. The Indianapolis drug giant scooped up the San Diego biotech for ...</p>
                    
                    <a href="https://endpoints.news/lilly-was-the-only-pharma-bidder-for-ventyx/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Insurance CEOs defend their businesses at House hearing
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-23 12:10</span>
                        
                    </div>
                    
                    <p class="news-summary">The CEOs of the biggest US health insurers defended their business practices before a House hearing Thursday on the soaring cost of health coverage. Republican and Democratic lawmakers slammed insurers for hiking premiums, delaying care ...</p>
                    
                    <a href="https://endpoints.news/insurance-ceos-defend-their-businesses-at-house-hearing/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        High court picked Hikmaâ€™s â€˜skinny labelâ€™ fight after letting the issue â€˜percolateâ€™
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-22 19:53</span>
                        
                    </div>
                    
                    <p class="news-summary">Generic and brand-name drugmakers have been divided for decades over the use of â€œskinny labelsâ€ to bring lower-cost drugs to market. Now, the Supreme Court is taking up the issue. Itâ€™s wading into a case ...</p>
                    
                    <a href="https://endpoints.news/high-court-picked-hikmas-skinny-label-fight-after-letting-the-issue-percolate/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drugmakers spent less on Washington lobbying in 2025&#39;s final quarter
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-22 18:35</span>
                        
                    </div>
                    
                    <p class="news-summary">The top five biopharma company spenders on congressional lobbying spent slightly less in Washington in the final quarter of 2025 than they did in the previous quarter, the latest Senate disclosures show. Pfizer and Johnson ...</p>
                    
                    <a href="https://endpoints.news/drugmakers-spent-less-on-washington-lobbying-in-2025s-final-quarter/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Corcept&#39;s drug extends patients&#39; lives in key ovarian cancer study
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-22 16:08</span>
                        
                    </div>
                    
                    <p class="news-summary">Corcept Therapeutics said its experimental drug cut the risk of death by 35% for patients with a challenging form of ovarian cancer when added on top of chemotherapy, notching an important win after the California ...</p>
                    
                    <a href="https://endpoints.news/corcepts-drug-extends-patients-lives-in-key-ovarian-cancer-study/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        China-founded pharma Corxel raises up to $287M for oral GLP-1
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-22 16:00</span>
                        
                    </div>
                    
                    <p class="news-summary">Since its 2019 founding, Corxel Pharmaceuticals has evolved from focusing on the China market to eyeing the world. The biopharma, founded in Shanghai but now headquartered in New Jersey, has raised as much as ...</p>
                    
                    <a href="https://endpoints.news/china-founded-pharma-corxel-raises-up-to-287m-for-oral-glp-1/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Health insurance CEOs head to DC
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-22 15:39</span>
                        
                    </div>
                    
                    <p class="news-summary">We donâ€™t know if President Donald Trump made good on plans to meet with major health insurers yet, but their CEOs are slated to testify today before two congressional committees ...</p>
                    
                    <a href="https://endpoints.news/health-insurance-ceos-head-to-dc/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Bristol Myers signs deal with Janux on T cell engager for $50M upfront
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-22 15:15</span>
                        
                    </div>
                    
                    <p class="news-summary">Janux Therapeutics has found a new partner. The San Diego-based biotech is teaming up with Bristol Myers Squibb on a solid tumor program, but the target is not yet disclosed. Bristol ...</p>
                    
                    <a href="https://endpoints.news/bristol-myers-signs-deal-with-janux-on-t-cell-engager-for-50m-upfront/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Erasca, Corvus, BioAge target $500M+ offerings
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-22 14:43</span>
                        
                    </div>
                    
                    <p class="news-summary">Plus, news about Ipsen, Galderma, PAQ Therapeutics and Resolve M Therapeutics: ğŸ’° Public offering roundup: Erasca is selling more than 22 million shares at $10 apiece, targeting $225 million in ...</p>
                    
                    <a href="https://endpoints.news/erasca-corvus-bioage-target-500m-offerings/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        #JPM26: Hua Medicine plots diabetes drug expansion in China and beyond
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-22 12:00</span>
                        
                    </div>
                    
                    <p class="news-summary">Shanghai-based Hua Medicine wants to capture a greater share of the global diabetes market with a different approach from popular GLP-1 medicines. Many newer diabetes drugs mimic gut hormones to regulate glucose. Hua&#39;s drug for ...</p>
                    
                    <a href="https://endpoints.news/hua-medicine-plots-diabetes-drug-expansion-in-china-and-beyond/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        BioMarin vets spearhead new biotech with $82M for rare disease drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-22 12:00</span>
                        
                    </div>
                    
                    <p class="news-summary">A fresh biotech has raised $82 million to scour the landscape of rare disease medicines that need a new home for further development and apply lessons from executives&#39; experiences at BioMarin. The Bay Area startup ...</p>
                    
                    <a href="https://endpoints.news/biomarin-vets-spearhead-new-biotech-with-82m-for-rare-disease-drugs/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        The status of EU drug price talks depends on who you ask
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-21 20:33</span>
                        
                    </div>
                    
                    <p class="news-summary">One of the main questions for drugmakers entering 2026, and one they hope tilts in their favor, is whether the US will successfully pressure Europe to raise the price it pays for drugs. Three weeks ...</p>
                    
                    <a href="https://endpoints.news/the-status-of-eu-drug-price-talks-depends-on-who-you-ask/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Johnson &amp; Johnson brushes off MFN impact, sees strong growth for 2026
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-21 16:43</span>
                        
                    </div>
                    
                    <p class="news-summary">As the calendar turns from JPM to quarterly reports, earnings bellwether Johnson &amp;amp; Johnson makes its return for 2026. The focus this time? How biopharma will react to a slate of most favored nation deals ...</p>
                    
                    <a href="https://endpoints.news/johnson-johnson-brushes-off-mfn-impact-sees-strong-growth-for-2026/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Tanabe pill delays blood disorder; enGene adds up to $100M from loans
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Endpoints News</span>
                        <span class="news-date">2026-01-21 16:25</span>
                        
                    </div>
                    
                    <p class="news-summary">Plus, news about IO, ErVimmune, Affibody, Clasp Therapeutics and Infinitopes: ğŸ’Š Tanabe Pharmaâ€™s pill succeeds in rare blood conditions: The biotechâ€™s oral melanocortin-1 receptor delayed the onset of symptoms in a ...</p>
                    
                    <a href="https://endpoints.news/tanabe-pill-delays-blood-disorder-engene-adds-up-to-100m-from-loans/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">ç»¼åˆ</h2>
                    <span class="category-title-en"></span>
                    <span class="category-count">40 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Samsung Bio sticks landing on 2025 as it becomes first Korean biopharma to hit 2T won profit threshold
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-22 07:36</span>
                        
                        <span class="news-importance">â­â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">CDMO Samsung Biologics grew sales more than 30% last year to around 4.6 trillion Korean won ($3.1 billion) and lifted its 2025 operating profit to roughly 2.07 trillion won ($1.4 billion). Samsung Bio is now the first Korean biotech or pharmaceutical company to surpass the 2 trillion won annual profit threshold, local news outlets reported this week.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/samsung-bio-sticks-landing-2025-it-becomes-first-korean-biopharma-hit-2-trillion-won-profit" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Bausch Health&#39;s $2B pursuit of Xifaxan successor hits wall with phase 3 failure
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-23 10:08</span>
                        
                        <span class="news-importance">â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">A potential inflection point that Bausch Health hoped could diversify its portfolio has vanished with a pair of phase 3 failures for a new formulation of the companyâ€™s bread-and-butter Xifaxanâ€”a setback that leaves a $2 billion hole in its growth plan.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/bausch-healths-2b-pursuit-xifaxan-successor-hits-wall-phase-3-failure" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        CEPI bankrolls $30M Ebola vaccine collaboration with Merck, SK Bioscience and others
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-22 10:54</span>
                        
                        <span class="news-importance">â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The project, which involves Merck, SK Bioscience, Hilleman Laboratories and CDMO IDT Biologika, aims to make Merck&#39;s current Ebola vaccine easier to manufacture and store, prompting broader global accessibility.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/cepi-bankrolls-30m-ebola-vaccine-collaboration-merck-sk-biosciences-and-others" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        IntraBio&#39;s Aqneursa, on a roll with EU approval, races toward another rare disease indication with phase 3 win
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-21 11:04</span>
                        
                        <span class="news-importance">â­â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The company announced a phase 3 win in the rare neurodegenerative disease Ataxia-telangiectasia on the same day it snagged a key European approval in the drug&#39;s original indication of Niemann-Pick disease type C.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/intrabios-aqneursa-roll-eu-approval-races-toward-another-rare-disease-indication-phase-3-win" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novo&#39;s Wegovy pill launch wows with strong early uptake: analysts
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-23 09:42</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">In the second week of oral Wegovyâ€™s launch, which ended Jan. 16, the obesity pill logged roughly 18,400 total prescriptions, according to IMS data cited by Jefferies. That performance is a fair bit better than that of either injectable Wegovy or Eli Lilly&#39;s Zepbound during the first two weeks of their respective rollouts, the analyst team noted.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/novos-impressive-wegovy-pill-launch-headline-and-itself-evercore-says" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Fierce Pharma Asiaâ€”Astellas CEO&#39;s BD plan; Takeda&#39;s US layoffs; Chugai&#39;s chase for name recognition
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-22 15:31</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Astellas CEO said he doesn&#39;t want to make acquisitions simply to fill a revenue gap. Takeda is preparing for Trintellix&#39;s U.S. patent expiry with a round of layoffs. Chugai&#39;s CEO is seeking name recognition as the Roche unit looks for more external partners. And more.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/astellas-ceo-bd-plan-takeda-us-layoffs-chugai-chase-name-recognition" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Biosimilar execs optimistic about future for US biosims as Sandoz locks in on â€˜golden decadeâ€™ to come
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-21 17:07</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Executives from top U.S. biosimilar makers are optimistic about the future of U.S. biosimilar adoption as recent FDA guidance seeks to streamline biosimilar development and potentially dissipate the upcoming â€œbiosimilar void.â€</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/biosimilar-execs-remain-optimistic-state-us-biosimilars-while-sandoz-locks-golden-decade" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Led by Darzalex surge, J&amp;amp;J expects revenue to reach $100B in 2026
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-21 11:20</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Led by cancer standout Darzalex, Johnson &amp;amp; Johnson projects that its 2026 revenue will reach between $100 billion and $101 billion. With J&amp;amp;J also forecasting double-digit revenue increases by the end of the decade, the drugmaker may be on its way to kicking off a $100-billion-plus annual revenue streak.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/led-darzalex-surge-jj-expects-revenue-reach-100b-2026" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about drug shortages, llama antibodies for developing meds, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-23 14:27</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The number of ongoing prescription drug shortages rose slightly in the last quarter of 2025, but remained significantly lower than the all-time high reached in 2024</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/23/moderna-vaccines-cigna-shortages-cancer-obesity-weight/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: The number of new drug shortages in U.S. hits lowest level in 20 years, but myriad problems remain
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-22 17:40</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The number of ongoing prescription drug shortages rose slightly in the last quarter of 2025, but remained significantly lower than the all-time high reached in the beginning of 2024.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/22/medicines-pharma-biotech-shortages-hospitals-injectables/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about Canada speeding drug reviews, Novo Nordisk ads, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-21 14:14</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Health Canada is planning to speed up reviews of some drugs by piggybacking on the decisions of foreign regulators, including possibly the U.S. FDA</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/21/canada-vaccines-novo-eczema-diabetes/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: GSK to buy RAPT Therapeutics, maker of food allergy treatment, in $2.2B deal
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-20 08:01</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">GSK is buying RAPT Therapeutics in a deal worth $2.2 billion, picking up an experimental medicine for food allergies.</p>
                    
                    <a href="https://www.statnews.com/2026/01/20/gsk-rapt-therapeutics-acquisition-food-allergy-prophylaxis-ozureprubart/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Anti-vaccine sentiment pushes Moderna away from new late-stage infectious disease trials
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-23 11:55</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans to pull away from late-stage clinical trial investments in the area.</p>
                    
                    <a href="https://www.fiercepharma.com/biotech/anti-vaccine-sentiment-pushes-moderna-away-new-late-stage-infectious-disease-trials" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Lilly battles weight stigma in short film centering obesity conversation on health, not appearance
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-23 11:52</span>
                        
                    </div>
                    
                    <p class="news-summary">GLP-1 giant Eli Lilly has once again taken to the medium of short film to get an important message about obesity across.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/lilly-battles-weight-stigma-short-film-centering-obesity-conversation-health-not" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        RFK Jr.&#39;s new ACIP chair stresses &#39;individual autonomy,&#39; questions polio shot guidance on podcast
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-23 10:19</span>
                        
                    </div>
                    
                    <p class="news-summary">The new chairman of the CDC&#39;s Advisory Committee on Immunization Practices, Kirk Milhoan, M.D., Ph.D., recently took to the podcast â€œWhy Should I Trust You?â€ to answer exactly that.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/new-acip-chair-talks-established-science-polio-vaccine-uncertainty-and-individual-autonomy" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        ST Pharm inks $56M deal to produce API for a US biotech
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-23 10:15</span>
                        
                    </div>
                    
                    <p class="news-summary">ST Pharm has struck a $56 million deal with an undisclosed U.S.-based biotech to produce active pharmaceutical ingredients (APIs) for a new oligonucleotide treatment. The Korean CDMO revealed the contract Friday in a regulatory filing.</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/st-pharm-inks-56m-deal-produce-apis-us-biotech" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Ocular drafts Eylea launch architect to lead attack on Regeneron&#39;s blockbuster
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-23 07:18</span>
                        
                    </div>
                    
                    <p class="news-summary">Plotting a challenge to Regeneronâ€™s blockbuster Eylea, Ocular Therapeutix has hired â€œa key architectâ€ of its rivalâ€™s launch to head its commercial team.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/ocular-drafts-eylea-launch-architect-lead-attack-regenerons-blockbuster" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        JPM26: Sunshine, AI and the deals that weren&#39;t
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-22 10:09</span>
                        
                    </div>
                    
                    <p class="news-summary">Fierceâ€™s Zoey Becker, Angus Liu and Gabrielle Masson unpack the key topics and trends that stood out at this yearâ€™s J.P. Morgan Healthcare Conference.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/recapping-2026-jp-morgan-healthcare-conference" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Global pharma manufacturing output surged in &#39;25 in &#39;front-loading&#39; response to US tariff threats: report
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-22 15:19</span>
                        
                    </div>
                    
                    <p class="news-summary">While the threat of U.S. import tariffs prompted a surge in drug production last year, that output is slated to slow across multiple geographies in 2026, according to a new report from financial services firm Atradius.</p>
                    
                    <a href="https://www.fiercepharma.com/manufacturing/pharma-manufacturing-output-surged-25-countries-braced-us-tariffs-atradius" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Invivyd teams up with Olympic skier Lindsey Vonn for antibody education
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-22 10:54</span>
                        
                    </div>
                    
                    <p class="news-summary">As Lindsey Vonnâ€™s comeback run heads toward a peak with Team USA at the upcoming 2026 Winter Olympics, Invivyd is adding the professional skier to its team, too.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/invivyd-teams-olympic-skier-lindsey-vonn-antibody-education" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Lundbeck â€˜not willing to compromiseâ€™ on M&amp;amp;A strategy after missed Avadel attempt: exec
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-22 10:23</span>
                        
                    </div>
                    
                    <p class="news-summary">Despite falling short in its recent bid to snatch Avadel from Alkermes, Lundbeck is signaling to investors that itâ€™s not desperate for deals and will not lower its standards for future M&amp;amp;A transactions.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/lundbeck-not-willing-compromise-ma-strategy-after-missed-avadel-attempt" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Trump&#39;s Davos drug pricing claims decried as &#39;fake news&#39; by French presidency
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-22 09:57</span>
                        
                    </div>
                    
                    <p class="news-summary">After U.S. President Donald Trump took the stage at the World Economic Forum this week to tout the supposed success of his tariff-tinged trade negotiations, the French presidency has pushed back against a drug pricing claim that itâ€™s branding â€œfake news.â€</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/trumps-davos-drug-pricing-claims-decried-fake-news-french-presidency" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        In J&amp;amp;J talc litigation, N.J. court-appointed official recommends allowing expert testimony
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-21 15:13</span>
                        
                    </div>
                    
                    <p class="news-summary">In Johnson &amp;amp; Johnson&#39;s long-running talc litigation, a court-appointed special master has recommended that plaintiffs should be able to present testimony from expert witnesses who can speak to scientific evidence backing their claims. The decision could negatively impact the company&#39;s defense of lawsuits from those who claim Johnsonâ€™s Baby Powder caused their cancer.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/jj-talc-litigation-nj-court-recommends-allow-expert-testimony" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        UPDATE: In quick reversal, Trump calls off tariff threat related to Greenland pursuit
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-20 09:55</span>
                        
                    </div>
                    
                    <p class="news-summary">Only a few days after threatening to impose new tariffs on a group of European countries related to his pursuit of Greenland, the president has called off the threat.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/trumps-new-tariff-threats-around-greenland-threaten-upend-eu-trade-deal" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Pfizer CEO lays blame for US vaccine woes on RFK Jr.&#39;s &#39;anti-science&#39; stance: WSJ
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-21 09:46</span>
                        
                    </div>
                    
                    <p class="news-summary">While much of the biopharma industry has spent the past 12 months treading lightly around the Trump administration and the tumult it has wrought on U.S. medical research and regulation, Pfizerâ€™s CEO cut to the chase this week in a blatant rebuke of HHS Secretary Robert F. Kennedy Jr., according to The Wall Street Journal.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/pfizer-ceo-lays-blame-us-vaccine-woes-anti-science-rfk-jr-wsj" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Rising Stars: Regeneronâ€™s Catie Matthews on updating marketing strategy to meet the AI boom
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-20 12:30</span>
                        
                    </div>
                    
                    <p class="news-summary">In a Q&amp;amp;A for Fierce Pharma Marketingâ€™s â€œRising Starsâ€ series, Catie Matthews suggested that marketers should embrace artificial intelligence in their own lives.</p>
                    
                    <a href="https://www.fiercepharma.com/marketing/rising-stars-regenerons-catie-matthews-updating-marketing-strategy-amid-ai-boom" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        GSK licenses Alteogen enzyme in bid to develop subQ Jemperli
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-20 14:08</span>
                        
                    </div>
                    
                    <p class="news-summary">GSK, through its oncology subsidiary Tesaro, is handing over $20 million upfront to Alteogen for global rights to the Korean biotechâ€™s novel hyaluronidase ALT-B4. Tesaro plans to use ALT-B4 to develop and potentially market a subcutaneous form of the ascendant cancer med Jemperli.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/gsk-offers-alteogen-285m-subq-jemperli-licensing-pact" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Takeda&#39;s neuroscience field force hit with layoffs as key patent loss looms for Trintellix
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FiercePharma</span>
                        <span class="news-date">2026-01-20 13:14</span>
                        
                    </div>
                    
                    <p class="news-summary">Takeda is executing another round of layoffs, cutting 243 roles in the U.S. The company is preparing for an upcoming patent loss on depression drug Trintellix.</p>
                    
                    <a href="https://www.fiercepharma.com/pharma/takeda-cuts-243-us-workers-generic-competition-looms-trintellix" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Up and down the ladder: The latest comings and goings
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-23 17:19</span>
                        
                    </div>
                    
                    <p class="news-summary">From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/23/pharma-biotech-jobs-teva-novartis-novo-lilly/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Insurers blame drugmakers, hospitals for high prices
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-23 15:26</span>
                        
                    </div>
                    
                    <p class="news-summary">Plus more biotech news updates, brought to you by The Readout</p>
                    
                    <a href="https://www.statnews.com/2026/01/23/biotech-news-insurers-blame-drugmakers-hospitals-for-prices/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Health insurance execs shift blame for costly, confusing health care system
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-22 20:11</span>
                        
                    </div>
                    
                    <p class="news-summary">Health insurance execs blame the high cost of health care on hospitals, doctors, and prescription drugs.</p>
                    
                    <a href="https://www.statnews.com/2026/01/22/health-insurance-execs-blame-high-costs-hospitals-doctors-pharma/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: France rebuffs Trump over drug-pricing boast
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-22 15:58</span>
                        
                    </div>
                    
                    <p class="news-summary">And more biotech news from The Readout newsletter</p>
                    
                    <a href="https://www.statnews.com/2026/01/22/biotech-news-2/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about Europeâ€™s pharma supply chain, stopping GLP-1 drugs, and more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-22 14:26</span>
                        
                    </div>
                    
                    <p class="news-summary">Many patients using GLP-1 drugs like Wegovy may not regain lost weight quickly when they stop treatment, an analysis of real-world data shows</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/22/europe-insulin-novo-weight-cvs-pharmacies/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Anthony Letai says NCI is more stable than perceived and is heading for a big year
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-22 09:30</span>
                        
                    </div>
                    
                    <p class="news-summary">Anthony Letai says the National Cancer Institute is more stable than perceived and is heading for a big year.</p>
                    
                    <a href="https://www.statnews.com/2026/01/22/national-cancer-institute-director-anthony-letai-q-and-a/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Novo strikes deal for diabetes cell therapies
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-21 14:53</span>
                        
                    </div>
                    
                    <p class="news-summary">And other biotech news, brought to you by The Readout newsletter</p>
                    
                    <a href="https://www.statnews.com/2026/01/21/biotech-news-novo-nordisk-acquires-aspect-biosystems/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Congress revives health care deal with PBM reforms
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-20 15:31</span>
                        
                    </div>
                    
                    <p class="news-summary">This is the web edition of D.C. Diagnosis, STAT&#39;s twice-weekly newsletter about the politics and policy of health and medicine.</p>
                    
                    <a href="https://www.statnews.com/2026/01/20/congress-revives-health-care-deal-pbm-reforms-dc-diagnosis-newsletter/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Benefit from Modernaâ€™s skin cancer immunotherapy endures
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-20 14:47</span>
                        
                    </div>
                    
                    <p class="news-summary">And other biotech news brought to you by the Readout Newsletter</p>
                    
                    <a href="https://www.statnews.com/2026/01/20/biotech-news-moderna-merck-skin-cancer-mrna/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Pharmalittle: Weâ€™re reading about drug prices in Europe, a cancer vaccine, and much more
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-20 14:20</span>
                        
                    </div>
                    
                    <p class="news-summary">U.S. pharmaceutical companies are stepping up their campaign for higher drug prices in Europe, in some cases threatening to withhold new medicines</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/20/pharma-prices-china-gsk-aids-cancer-vaccine-europe/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Florida proposes cutting eligibility for an AIDS drug program, causing panic
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-20 09:30</span>
                        
                    </div>
                    
                    <p class="news-summary">In a surprise move, Florida officials have proposed drastically reducing eligibility for the state AIDS drug assistance program.</p>
                    
                    <a href="https://www.statnews.com/pharmalot/2026/01/20/florida-hiv-aids-gilead-health-insurance/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        STAT+: Congress revives bipartisan health care proposal, including drug middlemen provisions
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">STAT News - Pharma</span>
                        <span class="news-date">2026-01-20 01:03</span>
                        
                    </div>
                    
                    <p class="news-summary">Elements of a health care deal that was blown up by Elon Musk are getting a fresh look in Congress.</p>
                    
                    <a href="https://www.statnews.com/2026/01/19/bipartisan-health-care-package-pharmacy-benefit-manager/?utm_campaign=rss" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">ç›‘ç®¡å®¡æ‰¹</h2>
                    <span class="category-title-en">Regulatory</span>
                    <span class="category-count">20 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drugs@FDA Data Files
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-23 13:58</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Drugs@FDA Downloadable Data File in ZIP format, Data Definitions, and Entity Relationship Diagram (ERD)</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Questions and Answers: Integration of FDA Facility Evaluation and Inspection Program for Human Drugs: A Concept of Operations
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-22 17:27</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Questions and Answers: Integration of FDA Facility Evaluation and Inspection Program for Human Drugs: A Concept of Operations</p>
                    
                    <a href="http://www.fda.gov/drugs/pharmaceutical-quality-resources/questions-and-answers-integration-fda-facility-evaluation-and-inspection-program-human-drugs-concept" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Registered Outsourcing Facilities
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-22 14:32</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Discover FDA&#39;s comprehensive list of registered outsourcing facilities engaged in human drug compounding. Get the latest updates, compliance guidelines, and resources to ensure safe, high-quality compounded medications. Explore regulations and stay informed with verified facility details.</p>
                    
                    <a href="http://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Bodynplant - Online Advisory Letter
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-22 14:21</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">FDA Online advisory letter issued to Bodynplant/bodynplant.com for serious disease claims, including: cancer, diabetes, and HIV-AIDS</p>
                    
                    <a href="http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/bodynplant-online-advisory-letter" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        What&#39;s New Related to Drugs
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-21 22:55</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Want to know what&#39;s new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.</p>
                    
                    <a href="http://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drug Trials Snapshots
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-21 22:45</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Drug Trials Snapshots: breaking down the what, how and why. Drug Trials Snapshots is part of an overall FDA effort to make demographic data more available and transparent.</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        C3TI Compass (Knowledge Repository)
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-22 14:46</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Centralized knowledge repository for clinical trial innovation</p>
                    
                    <a href="http://www.fda.gov/about-fda/cder-center-clinical-trial-innovation-c3ti/c3ti-compass-knowledge-repository" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Bayesian Statistical Analysis (BSA) Demonstration Project
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-22 14:45</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">C3TI aims to increase experience in Bayesian statistical methods in simple trial settings across sponsors, CDER clinical reviewers, and CDER statisticians, including deepening an understanding of their applicability, opportunities, and challenges.</p>
                    
                    <a href="http://www.fda.gov/about-fda/cder-center-clinical-trial-innovation-c3ti/bayesian-statistical-analysis-bsa-demonstration-project" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Clinical Outcome Assessment (COA): Frequently Asked Questions
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-22 13:16</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Clinical Outcome Assessments (COA) Frequently Asked Questions</p>
                    
                    <a href="http://www.fda.gov/about-fda/clinical-outcome-assessment-coa-frequently-asked-questions" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Genetic Metabolic Diseases Advisory Committee (GeMDAC) Charter
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-23 21:18</span>
                        
                    </div>
                    
                    <p class="news-summary">The Genetic Metabolic Diseases Advisory Committee (GeMDAC) advises the Commissioner of Food and Drugs or designee in discharging responsibilities as they relate to helping to ensure safe and effective drugs and biologic products for human use and as required.</p>
                    
                    <a href="http://www.fda.gov/advisory-committees/genetic-metabolic-diseases-advisory-committee/genetic-metabolic-diseases-advisory-committee-gemdac-charter" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Real-World Evidence
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-23 18:08</span>
                        
                    </div>
                    
                    <p class="news-summary">Real-world data (RWD) and real-world evidence (RWE) played an increasing role in health care decisions. The 21st Century Cures Act, passed in 2016, placed additional focus on the use of these types of data to support regulatory decision making.</p>
                    
                    <a href="http://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Generic Drug User Fee Amendments
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-23 18:02</span>
                        
                    </div>
                    
                    <p class="news-summary">This page features news and information for industry and stakeholders about GDUFA, its fee structure, payment methods, and related information.</p>
                    
                    <a href="http://www.fda.gov/industry/fda-user-fee-programs/generic-drug-user-fee-amendments" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Office of New Drugs Custom Medical Queries (OCMQs)
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-23 17:08</span>
                        
                    </div>
                    
                    <p class="news-summary">Office of New Drugs Custom Medical Queries (OCMQs) are standardized groupings of similar adverse event terms intended to assist with the identification of potential safety issues during review of adverse event data.</p>
                    
                    <a href="http://www.fda.gov/drugs/development-resources/office-new-drugs-custom-medical-queries-ocmqs" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drug Shortages
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-23 16:48</span>
                        
                    </div>
                    
                    <p class="news-summary">Drug Shortages Homepage</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        List of Drug Master Files (DMFs)
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-23 15:41</span>
                        
                    </div>
                    
                    <p class="news-summary">The list is updated quarterly.&amp;nbsp;Changes are made to the DMF activity status, DMF type, holder name, and subject.</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-master-files-dmfs/list-drug-master-files-dmfs" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Novel Drug Approvals for 2025
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-23 15:35</span>
                        
                    </div>
                    
                    <p class="news-summary">Innovative drugs often mean new treatment options for patients and advances in health care for the American public.</p>
                    
                    <a href="http://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-23">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Generic Drug Facilities, Sites and Organization Lists
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-23 13:52</span>
                        
                    </div>
                    
                    <p class="news-summary">Generic Drug Facilities, Sites and Organization Lists</p>
                    
                    <a href="http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drug-facilities-sites-and-organization-lists" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Products Claiming to &#34;Cure&#34; Cancer Are a Cruel Deception
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-22 14:03</span>
                        
                    </div>
                    
                    <p class="news-summary">Many ads on social media and &#34;healthy&#34; websites claim their products can cure cancer. They cannot.</p>
                    
                    <a href="http://www.fda.gov/consumers/consumer-updates/products-claiming-cure-cancer-are-cruel-deception" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Advisory Letters
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-22 13:44</span>
                        
                    </div>
                    
                    <p class="news-summary">Advisory Letters</p>
                    
                    <a href="http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/advisory-letters" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Drug Trials Snapshots KYGEVVI
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">FDA News</span>
                        <span class="news-date">2026-01-21 22:43</span>
                        
                    </div>
                    
                    <p class="news-summary">Drug Trials Snapshots KYGEVVI</p>
                    
                    <a href="http://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-kygevvi" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
            <section class="category">
                <div class="category-header">
                    <h2 class="category-title">å•†ä¸šåŠ¨æ€</h2>
                    <span class="category-title-en">Business/M&amp;A</span>
                    <span class="category-count">8 æ¡</span>
                </div>

                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        ErVimmune raises 17m euros in funding to develop cancer vaccine
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-22 14:10</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The vaccine could be created as a ready-to-use product, rather than needing to be personalised</p>
                    
                    <a href="https://pharmatimes.com/news/ervimmune-raises-17m-euros-in-funding-to-develop-cancer-vaccine/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-19">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-19 14:34</span>
                        
                        <span class="news-importance">â­â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Decision introduces zolbetuximab for eligible patients in NHS Scotland</p>
                    
                    <a href="https://pharmatimes.com/news/scottish-medicines-consortium-becomes-first-in-uk-to-adopt-new-precision-gastric-cancer-treatment/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        AAX Biotech and Vascurie announce new neuro-oncology collaboration
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-20 12:41</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">The collaboration will help to advance a pipeline of antibody candidates</p>
                    
                    <a href="https://pharmatimes.com/news/aax-biotech-and-vascurie-announce-new-neuro-oncology-collaboration/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-19">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-19 14:42</span>
                        
                        <span class="news-importance">â­</span>
                        
                    </div>
                    
                    <p class="news-summary">Company prepares marketing submission after treatment shows strong efficacy</p>
                    
                    <a href="https://pharmatimes.com/news/nxera-pharma-reports-positive-results-from-phase-3-insomnia-trial-in-south-korea/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-22">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Book your tickets and join the PM Society for the 40th PM Awards on 20 March 2026
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-22 12:36</span>
                        
                    </div>
                    
                    <p class="news-summary">The PM Awards celebrate creativity in pharmaceutical marketing and healthcare communications</p>
                    
                    <a href="https://pharmatimes.com/news/book-your-tickets-and-join-the-pm-society-for-the-40th-pm-awards-on-20-march-2026/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Sun Pharmaâ€™s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-21 12:13</span>
                        
                    </div>
                    
                    <p class="news-summary">More than 71% of patients treated with Unloxcyt achieved disease control</p>
                    
                    <a href="https://pharmatimes.com/news/sun-pharmas-unloxcyt-now-available-in-us-for-advanced-cutaneous-squamous-cell-carcinoma/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-21">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Peter Llewellyn-Davies
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-21 12:02</span>
                        
                    </div>
                    
                    <p class="news-summary">ARTCLINE appoints Peter Llewellyn-Davies as Chairman of its Supervisory Board</p>
                    
                    <a href="https://pharmatimes.com/appointments/peter-llewellyn-davies/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
                <article class="news-card" data-date="2026-01-20">
                    <h3>
                        <span class="lang-flag">ğŸ‡ºğŸ‡¸</span>
                        Venner Shipley announces opening of new Bristol office
                    </h3>
                    <div class="news-meta">
                        <span class="news-source">Pharma Times</span>
                        <span class="news-date">2026-01-20 12:42</span>
                        
                    </div>
                    
                    <p class="news-summary">The firm already has a number of offices across the UK and Europe</p>
                    
                    <a href="https://pharmatimes.com/news/venner-shipley-announces-opening-of-new-bristol-office/" target="_blank" rel="noopener" class="news-link">é˜…è¯»åŸæ–‡</a>
                </article>
                
            </section>
            
        </main>

        <footer>
            <p>Generated by <strong>Pharma Daily</strong> - åˆ¶è¯èµ„è®¯èšåˆç³»ç»Ÿ</p>
            <p>2026-01-24 03:25</p>
        </footer>
    </div>

    <script>
    (function() {
        // ========== Theme Switcher ==========
        const themeBtns = document.querySelectorAll('.theme-btn');
        const savedTheme = localStorage.getItem('pharma-daily-theme') || 'minimal';

        function setTheme(theme) {
            document.body.setAttribute('data-theme', theme);
            themeBtns.forEach(btn => {
                btn.classList.toggle('active', btn.getAttribute('data-theme') === theme);
            });
            localStorage.setItem('pharma-daily-theme', theme);
        }

        // Apply saved theme on load
        setTheme(savedTheme);

        themeBtns.forEach(btn => {
            btn.addEventListener('click', function() {
                setTheme(this.getAttribute('data-theme'));
            });
        });

        // ========== Date Filter ==========
        const filterBtns = document.querySelectorAll('.date-btn');
        const newsCards = document.querySelectorAll('.news-card');
        const filterCount = document.getElementById('filterCount');
        const categories = document.querySelectorAll('.category');

        function updateFilter(selectedDate) {
            let visibleCount = 0;

            newsCards.forEach(card => {
                const cardDate = card.getAttribute('data-date');
                if (selectedDate === 'all' || cardDate === selectedDate) {
                    card.classList.remove('hidden');
                    visibleCount++;
                } else {
                    card.classList.add('hidden');
                }
            });

            // Hide empty categories
            categories.forEach(category => {
                const visibleCards = category.querySelectorAll('.news-card:not(.hidden)');
                category.style.display = visibleCards.length > 0 ? 'block' : 'none';

                // Update category count
                const countSpan = category.querySelector('.category-count');
                if (countSpan) {
                    countSpan.textContent = visibleCards.length + ' æ¡';
                }
            });

            // Update filter count display
            if (selectedDate === 'all') {
                filterCount.textContent = '';
            } else {
                filterCount.textContent = `æ˜¾ç¤º ${visibleCount} æ¡æ–°é—»`;
            }
        }

        filterBtns.forEach(btn => {
            btn.addEventListener('click', function() {
                filterBtns.forEach(b => b.classList.remove('active'));
                this.classList.add('active');
                updateFilter(this.getAttribute('data-filter'));
            });
        });
    })();
    </script>
</body>
</html>